Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Treasury Shares: 2021-2025

Historic Treasury Shares for CytomX Therapeutics (CTMX) over the last 4 years, with Sep 2025 value amounting to $2.9 million.

  • CytomX Therapeutics' Treasury Shares rose 60.00% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 60.00%. This contributed to the annual value of $1.9 million for FY2024, which is 32.32% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Treasury Shares is $2.9 million, which was up 0.16% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Treasury Shares peaked at $2.9 million during Q3 2025, and registered a low of $868,250 during Q4 2021.
  • Its 3-year average for Treasury Shares is $2.0 million, with a median of $1.8 million in 2024.
  • Data for CytomX Therapeutics' Treasury Shares shows a peak YoY soared of 72.30% (in 2023) over the last 5 years.
  • CytomX Therapeutics' Treasury Shares (Quarterly) stood at $868,250 in 2021, then soared by 39.69% to $1.2 million in 2022, then rose by 15.47% to $1.4 million in 2023, then spiked by 32.32% to $1.9 million in 2024, then skyrocketed by 60.00% to $2.9 million in 2025.
  • Its Treasury Shares was $2.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.8 million in Q1 2025.